You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Foundayo ™ (orforglipron) tablet
0.8 mg / 2.5 mg / 5.5 mg / 9 mg / 14.5 mg / 17.2 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can Foundayo™ (orforglipron) be used in people with renal impairment?
The intrinsic factor of renal impairment (eGFR 27.8 to 156 mL/min/1.73 m2) does not have a clinically relevant effect on the PK of orforglipron, therefore, no dosage adjustment of orforglipron is recommended for patients with renal impairment.
See important safety information, including boxed warning, in the attached prescribing information.
Orforglipron Use in People With Renal Impairment
No dosage modification of orforglipron is recommended for patients with renal impairment.1
In subjects with renal impairment including end-stage renal disease (ESRD), no change in orforglipron pharmacokinetics (PK) was observed.1
Monitor renal function in patients reporting adverse reactions to orforglipron that could lead to volume depletion.1
Orforglipron Pharmacokinetics
The intrinsic factor of renal impairment (estimated glomerular filtration rate [eGFR] 27.8 to 156 mL/min/1.73 m2) does not have a clinically relevant effect on the PK of orforglipron.1
Renal impairment does not impact the PK of orforglipron. The PK of orforglipron after a single oral 0.8 mg dose were evaluated in patients with severe renal impairment and ESRD compared with subjects who had normal renal function.1
Data from clinical trials have also shown that renal impairment in patients with overweight or obesity does not impact the PK of orforglipron.1
Acute Kidney Injury Due to Volume Depletion
There have been reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with glucagon-like peptide-1 (GLP-1) receptor agonists or orforglipron.1
The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea.1
Monitor renal function in patients reporting adverse reactions to orforglipron that could lead to volume depletion, especially during dosage initiation and escalation of orforglipron.1
Postmarketing Experience Related to Renal and Urinary Disorders
The following adverse reactions have been reported during post-approval use of GLP-1 receptor agonists. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.1
Renal and Urinary Disorders: acute renal failure or worsening of chronic renal failure, sometimes requiring hemodialysis.1
Enclosed Prescribing Information
References
1Foundayo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2026.
Date of Last Review: September 17, 2026